The FDA’s CDER has released 2023 Annual Reports for its Offices of New Drugs (OND) and Translational Services (OTS), highlighting activities that span dozens of drug approvals and guidances from developing AI-enabled software prototypes to identify adverse drug events.
Source: Drug Industry Daily